How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer-Reference-Cited by-同舟云学术

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

Published:2019-06 Issue:6 Volume:30 Page:884-896
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Peters S.,Reck M.,Smit E.F.,Mok T.,Hellmann M.D.

Funder

Merck Sharp & Dohme Corp.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz109/28572661/mdz109.pdf

Reference100 articles.

1. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines). Non-Small Cell Lung Cancer, Version 8, 2017; https://www.nccn.org (18 July 2017, date last accessed).

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

5. A systematic review of targeted agents for non-small cell lung cancer;Vestergaard;Acta Oncol,2018

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shrinking sample sizes in lung cancer trials: Various explanations, open questions;European Journal of Cancer;2024-03

2. The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab;International Journal of Cardiology;2024-02

3. ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis;PLOS ONE;2024-01-23

4. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review;Medicine;2024-01-19

5. Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics;Journal of Translational Medicine;2024-01-10